BiomX Inc.

BiomX Inc. (PHGE) is a clinical-stage biopharmaceutical company that completed its public listing in 2019 via a SPAC merger with Chardan NexTech Acquisition Corp, sponsored by Chardan Capital Markets. Headquartered in Israel with U.S. operations, BiomX operates in the biotechnology sector and develops phage-based therapies targeting specific bacteria implicated in chronic diseases, with programs spanning chronic rhinosinusitis and inflammatory bowel disease. The company filed an 8-K current report with the SEC on April 10, 2026, under accession number 0001213900-26-042200, remaining an active SEC reporting entity. To access BiomX's full filing history, SPAC deal data, and real-time monitoring tools, sign up for complete access on SpacDesk.